Európai Unió - angol - EMA (European Medicines Agency)

merck europe b.v.  - follitropin alfa, lutropin alfa - infertility, female - sex hormones and modulators of the genital system, - pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (lh) and follicle-stimulating-hormone deficiency.in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Szingapúr - angol - HSA (Health Sciences Authority)

merck pte. ltd. - lutropin alfa - injection, powder, for solution - 3.7μg (82.5iu) (10% overage) - lutropin alfa 75 iu/vial

Európai Unió - angol - EMA (European Medicines Agency)

merck europe b.v.  - lutropin alfa - ovulation induction; infertility, female - sex hormones and modulators of the genital system, - luveris in association with a follicle-stimulating-hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (lh) and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level

Izrael - angol - Ministry of Health

merck serono ltd - luteinizing hormone - powder for solution for injection - luteinizing hormone 75 iu/ml - gonadotropins - luveris in association with a follicle stimulating hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 40 ml - injection, solution - excipient ingredients: - treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 20 ml - injection, solution - excipient ingredients: - treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Izrael - angol - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - powder and solvent for solution for injection - follitropin alfa 150 iu; lutropin alfa 75 iu - follitropin alfa - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1560 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1092 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 3 ml - injection, diluent for - excipient ingredients: - berinert iv is indicated for the treatment of acute attacks in patients with hereditary angioedema (hae).